Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Irinotecan in Indolent Lymphoproliferative Malignancies
NCT00005626Phase 2Completed
- Sponsor
- Moffitt Cancer Center
- Start
- Feb 1998
- Primary completion
- Nov 2003
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of irinotecan in non-Hodgkin lymphoma (NHL), chronic lymphocytic leukemia (CLL) and prolymphocytic leukemia (PLL), sponsored by Moffitt Cancer Center. Primary endpoint: Objective Response Rate at 5 years. Started Feb 1998; status: completed.
02
Drugs
irinotecan
03
Conditions
non-Hodgkin lymphoma (NHL)chronic lymphocytic leukemia (CLL)prolymphocytic leukemia (PLL)
Beyond the preview
Go deeper on NCT00005626.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00005626.